Biotype GmbH, a German biotechnology company with over 20 years of history, has successfully positioned itself as a trusted provider of state-of-the-art solutions for molecular diagnostics in Europe. Biotype develops, manufactures, and distributes molecular in-vitro diagnostic kits for the detection and quantification of DNA and RNA-based biomarkers. The assays support diagnosis and therapy in various molecular applications, such as oncology, infectious diseases, forensics, dermatology, and veterinary. Biotype initially started as a biotechnology company developing molecular diagnostic tests and has grown into a full-service provider offering the complete value chain in molecular in-vitro diagnostics. All our in-house developed tests are multiplex PCR-based and run either on established laboratory platforms or on our proprietary Modaplex device. The Modaplex system provides a novel real-time quantification procedure through the unique combination of PCR and simultaneous capillary electrophoresis. This technology enables the examination of up to 50 RNA and DNA markers in a single sample. With little hands-on time and a simple workflow, it allows to detect all types of genetic aberrations. Biotype’s contract development & manufacturing services cover all challenges from the idea up to the realization of a marketable product. One of our assets is platform and biomarker flexibility, meaning we design and develop molecular diagnostic assays optimized to customer needs, ranging from a prototype via RUO to CE-IVD. The company's goal is to provide customers, such as laboratories, pharmaceutical, and diagnostic companies, with quality and robust molecular diagnostic tools and services.